Pryor Cashman represented Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, in its execution of a License Agreement with Hongene Biotechnology Limited, a China-based international company, with respect to the development, supply and commercialization certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide chemistry.  

Representing Marina Biotech, Inc were Partners Lawrence Remmel, Chair of Pryor Cashman’s Banking and Finance Group, and Stephen Goodman.